Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis

ABSTRACT

Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafme [Lamisil] on Candida vaginitis versus clotrimazole. In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group [32 cases] was treated with clotrimazole and the next [25 cases] with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared. Our results shows that 12 [37.5%] patients were completely treated with clotrimazole during two weeks and, 6[18.8%] patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen [43.8%] patients showed moderate response and clotrimazole therapy was extended for one more week. When Lamisil was administrated, 19 [76.0%] patients were completely treated with Lamisil in two weeks, and 1 [4.0%] of the patients did not respond to the drug and was refereed for fluconazole therapy. Five [20.0%] of our patients showed moderate response and Lamisil therapy was extended for one more week. Our results show that vaginal cream, 1% Lamisil, could be suggested as a first-line treatment in vulvovaginal candidiasis